2011³âµµ ´ÜÀÏ º´¿ø¿¡¼­ °æÇèÇÑ °£¾Ï ±¹°¡¾Ï°ËÁø»ç¾÷
The Korean National Liver Cancer Surveillance Program: Experience of a Single Healthcare Center in 2011

´ëÇѳ»°úÇÐȸÁö 2013³â 84±Ç 5È£ p.672 ~ p.680

½ÉÀçÁØ(Shin Jae-Jun) - °æÈñ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
¹ÚÇöÁø(Park Hyun-Jin) - °æÈñ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
±èÁ¤¿í(Kim Jung-Wook) - °æÈñ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
ȲÀºÁ¤(Hwang Eun-Jung) - °æÈñ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
ÀÌâ±Õ(Lee Chang-Kyun) - °æÈñ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
ÀåÀ翵(Jang Jae-Young) - °æÈñ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
¹Ú¼ºÁø(Park Seong-Jin) - °æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ¿µ»óÀÇÇб³½Ç
ÃÖÇö¸²(Choi Hyun-Rim) - °æÈñ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø Á÷¾÷ȯ°æÀÇÇаú±³½Ç
±èº´È£(Kim Byung-Ho) - °æÈñ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç

Abstract

¸ñÀû: °£¾Ï Á¶±â °ËÁøÀ» À§ÇÑ ±¹°¡¾Ï°ËÁø»ç¾÷ÀÇ À¯¿ë¼º°ú ¹®Á¦Á¡À» Á¶»çÇϱâ À§ÇØ ´ÜÀÏ º´¿ø¿¡¼­ ÀÏ ³â°£ °æÇèÇÑ °£¾Ï°ËÁø»ç¾÷ °á°ú¸¦ ºÐ¼®ÇÏ¿´´Ù.

¹æ¹ý: 2011³â 1¿ù 1ÀϺÎÅÍ 12¿ù 31ÀϱîÁö °æÈñ´ëÇб³º´¿ø¿¡¼­ °£¾Ï°ËÁøÀ» À§ÇØ º¹ºÎ ÃÊÀ½ÆÄ °Ë»ç ¶Ç´Â Ç÷û ¾ËÆÄÅÂ¾Æ´Ü¹é °Ë»ç(ÀÌÇÏ AFP)¸¦ ¹ÞÀº ¼ö°ËÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿´´Ù. À̵éÀÇ ±âº»ÀûÀΠƯ¼º, °£¾Ï ¹ß°ßÀ², ±×¸®°í °£¾ÏÀ» ¹ß°ßÇϱâ À§ÇØ ÁöÃâµÈ ÀÇ·á ºñ¿ëÀ» À§¾Ï°ú ºñ±³ Á¶»çÇÏ¿´´Ù.

°á°ú: ÀÏ ³â°£ 621¸íÀ» °ËÁøÇÏ¿© ÃÑ 5¸í(0.8%)ÀÇ °£¼¼Æ÷¾Ï(ÀÌÇÏ °£¾Ï)À» ¹ß°ßÇÏ¿´´Ù. ÀÌ Áß 4¸íÀº º¹ºÎ ÃÊÀ½ÆÄ °Ë»ç·Î ¹ß°ßµÇ¾ú°í ¸ðµÎ ±ÙÄ¡Àû Ä¡·á(¼ö¼ú 2¸í, °íÁÖÆÄÀÀ°í¼ú 2¸í)¸¦ ¹Þ¾Ò´Ù. ³ª¸ÓÁö ÇÑ ¸íÀº AFP »ó½ÂÀ¸·Î ¹ß°ßµÇ¾ú°í ħÀ±¼º °£¼¼Æ÷¾ÏÀ¸·Î Áø´Ü ÈÄ 2°³¿ù¸¸¿¡ »ç¸ÁÇÏ¿´´Ù. °ú°Å º´·ÂÀ» Á¶»çÇÒ ¼ö ÀÖ¾ú´ø 492¸í °¡¿îµ¥ 45%°¡ BÇü°£¿°À̾ú°í 5%°¡ CÇü°£¿°, 1%°¡ BÇü CÇü µ¿½Ã°¨¿°, 3%°¡ ¾ËÄڿüº °£°æº¯ÁõÀ» Æ÷ÇÔÇÑ ±âŸ °£°æº¯ÁõÀ̾ú´Ù. ³ª¸ÓÁö 46%ÀÇ ¼ö°ËÀÚµéÀº °£¾Ï °íÀ§ÇèÀÎÀÚ¸¦ Çϳªµµ °¡Áö°í ÀÖÁö ¾Ê¾Ò´Ù. °£¾Ï1¸íÀ» ¹ß°ßÇϱâ À§ÇØ »ç¿ëµÈ ÀÇ·á ºñ¿ëÀº ÃÑ 842¸¸¿øÀ̾ú°í ÀÌ´Â À§¾ÏÀÇ 4,506¸¸¿ø¿¡ ºñÇØ ³·Àº ¼öÁØÀ̾ú´Ù. ºñ´ë»óÀÚµéÀ» Á¦¿ÜÇÏ¿´À» ¶§ °£¾Ï °ËÁø ºñ¿ëÀº 556¸¸¿ø±îÁö ³·Ãâ ¼ö ÀÖ¾ú´Ù.

°á·Ð: °£¾Ï°ËÁø»ç¾÷ÀÇ È¿À²¼º°ú ÇüÆò¼ºÀ» ³ôÀ̱â À§ÇØ ÀûÀýÇÑ °íÀ§Ç豺 ¼±º°À» À§ÇÑ ´ëÃ¥ ¸¶·ÃÀÌ ½Ã±ÞÇÏ´Ù. ±¹°¡¾Ï°ËÁø»ç¾÷ÀÌ ÀûÀýÇÏ°Ô ¼öÇàµÈ´Ù¸é ¾à 1%ÀÇ ¼ö°ËÀÚ¿¡¼­ °£¾ÏÀ» ¹ß°ßÇÒ ¼ö ÀÖ´Ù. ¿ÏÄ¡°¡ °¡´ÉÇÑ Ãʱ⠰£¾ÏÀº ´ëºÎºÐ º¹ºÎ ÃÊÀ½ÆÄ °Ë»ç·Î ¹ß°ßµÇ¸ç AFP´Â Ãʱ⠰£¾Ï ¹ß°ß¿¡´Â À¯¿ë¼ºÀÌ ¶³¾îÁö´Â ÆíÀÌ´Ù.
Background/Aims: The aim of this study was to investigate outcomes and current status of the National Liver Cancer Screening Program in a single healthcare center.

Methods: Subjects received abdominal ultrasonography (US) and/or serum alpha-fetoprotein (AFP) testing from January 2011 to December 2012. The clinical characteristics of the subjects, detection rate of liver cancer, and direct medical costs were investigated.

Results: Among 621 subjects, five (0.8%) were newly detected with hepatocellular carcinoma. Four underwent curative treatment, and all were detected by US (two surgical resections and two radiofrequency ablations). The remaining patient, whose disease was detected by an elevated AFP level, was infiltrative type with a poor prognosis. Of 492 subjects whose medical history was revealed, 45% had hepatitis B, 5% had hepatitis C, 1% had both, and 3% had other liver cirrhosis including alcoholic cirrhosis. The remaining 46% of subjects had no risk factors for liver cancer. Direct medical costs were estimated at 8,420,000 Won for detecting a single case of liver cancer, which was much lower than that of stomach cancer at 45,060,000 Won. If the non-high risk subjects were excluded, the cost for a single case of liver cancer decreased to 5,560,000 Won.

Conclusions: The high-risk group should be more accurately defined by appropriate screening tests to optimize liver cancer surveillance. The detection rate by the liver cancer surveillance program was about 1%, and most tumors could be detected at the early stage by US. The role of AFP seemed to be small for early defection of liver cancer.

Å°¿öµå

°£¾Ï, Áý´Ü °ËÁø, º¹ºÎ ÃÊÀ½ÆÄ °Ë»ç, ¾ËÆÄžƴܹé
Liver Neoplasms, Mass Screening, Ultrasonography, Alpha-fetoprotein
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
The detection rate by the liver cancer surveillance program was about 1%; ÀÏ ³â°£ 621¸íÀ» °ËÁøÇÏ¿© ÃÑ 5¸í(0.8%)ÀÇ °£¾ÏÀ» ¹ß°ßÇÏ¿´´Ù
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå